Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Field & Main Bank

Field & Main Bank raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,785 shares of the medical research company’s stock after acquiring an additional 79 shares during the quarter. Field & Main Bank’s holdings in Thermo Fisher Scientific were worth $947,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the company. Linden Thomas Advisory Services LLC increased its holdings in Thermo Fisher Scientific by 8.8% in the third quarter. Linden Thomas Advisory Services LLC now owns 1,546 shares of the medical research company’s stock worth $783,000 after buying an additional 125 shares during the last quarter. Avestar Capital LLC increased its holdings in Thermo Fisher Scientific by 15.6% in the third quarter. Avestar Capital LLC now owns 1,135 shares of the medical research company’s stock worth $575,000 after buying an additional 153 shares during the last quarter. Harbor Capital Advisors Inc. increased its holdings in Thermo Fisher Scientific by 17.7% in the third quarter. Harbor Capital Advisors Inc. now owns 1,241 shares of the medical research company’s stock worth $628,000 after buying an additional 187 shares during the last quarter. Steward Financial Group LLC acquired a new position in Thermo Fisher Scientific during the third quarter valued at approximately $73,000. Finally, Commonwealth Equity Services LLC grew its holdings in Thermo Fisher Scientific by 0.8% during the third quarter. Commonwealth Equity Services LLC now owns 99,703 shares of the medical research company’s stock valued at $50,467,000 after purchasing an additional 835 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on TMO shares. Deutsche Bank Aktiengesellschaft increased their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday. HSBC raised their price objective on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Royal Bank of Canada raised their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. The Goldman Sachs Group raised their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $606.76.

Insider Activity

In other news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,277 shares of company stock worth $29,649,264. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $3.27 during midday trading on Monday, reaching $576.87. 962,347 shares of the company traded hands, compared to its average volume of 1,554,585. The firm has a market cap of $220.20 billion, a PE ratio of 37.00, a PEG ratio of 2.41 and a beta of 0.80. The stock’s 50-day simple moving average is $574.18 and its 200-day simple moving average is $531.06. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.56 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.